Skip to main content
SpringerLink
Log in

The risk of developing cancer is not increased among patients who received contaminated Viracept [nelfinavir]

  • Media release
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. EMEA.Studies assessed by the EMEA indicate no increased risk of developing cancer for patients who have taken Viracept contaminated with ethyl mesilate. Media Release: 24 Jul 2008. Available from: URL: http://www.emea.europa.eu

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The risk of developing cancer is not increased among patients who received contaminated Viracept [nelfinavir]. React. Wkly. 1213, 2 (2008). https://doi.org/10.2165/00128415-200812130-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200812130-00004

Keywords

Search

Navigation